Table 3 Allergic rhino-conjunctivitis-specific recommendations from ARIA/EAACI (from: Bousquet et al. 2020) [37]
From: Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model
With the current knowledge, in patients with COVID-19 infection, intra-nasal corticosteroid (including spray) can be continued in allergic rhinitis at the recommended dose |
Stopping local intra-nasal corticosteroid is not advised. Suppression of the immune system has not been proven and more sneezing after stopping means more spreading of the Coronavirus |
These recommendations are conditional since there is a paucity of data and they should be revised regularly with new knowledge |